Latest OxySure Systems News
Dec 2, 2015
. FRISCO, TX--(Marketwired - December 02, 2015) - OxySure Systems, Inc. ( OTCQB : OXYS ) ("OxySure," or the "Company"), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology and other innovative medical solutions, today announced the completion of its name change to OxySure Therapeutics, Inc. Julian Ross, CEO of OxySure, reiterated that, "The purpose of the name change is to better reflect the business and industry that the Company operates in. " Ross also reminded stakeholders that, "The name change also enhances the Company's positioning as it marches towards a Nasdaq uplisting and develops an institutional following. " The Company's ticker symbol will remain the same, OXYS, and the company's website will remain the same, www.oxysure.com . About OxySure Systems, Inc. OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com Forward-Looking Statements Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management's control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Systems, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Systems, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Systems, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2014. The following files are available for download:
OxySure Systems Frequently Asked Questions (FAQ)
When was OxySure Systems founded?
OxySure Systems was founded in 2004.
Where is OxySure Systems's headquarters?
OxySure Systems's headquarters is located at 2611 Internet Boulevard, Frisco.
What is OxySure Systems's latest funding round?
OxySure Systems's latest funding round is Other Investors.
Who are the investors of OxySure Systems?
Investors of OxySure Systems include Agave Capital.
Who are OxySure Systems's competitors?
Competitors of OxySure Systems include Senseonics, Mercator MedSystems, Cagenix, Acelity, Monica Healthcare and 7 more.
Compare OxySure Systems to Competitors
Acacian Emergency Solutions is developing a system that permits emergency medical personnel in ambulances to wirelessly transmit critical patient data to hospital emergency rooms in real time using existing cellular networks. This system substantially aims to improve patient care as the actions within a few minutes of an emergency can seriously affect a patient's future.
Respiratory and infusion therapy for patients at home. Acquired by Lincare Holdings, Inc.
Aksys has developed an automated personal hemodialysis system for patient-performed hemodialysis in alternative care settings such as the patient's home.
Actuality Medical develops systems for improving the precision, morbidity, and quality of radiation oncology and surgical excision for soft tissue indications - initially for prostate and breast cancer. The company's first product, PerspectaSeed 4D, will apply intra-operative dynamic dosing - "continuous GPS" - to prostate brachytherapy. It is designed to reduce hot spots and cold spots by continually monitoring the actual positions of placed seeds and recommending placements for subsequent seeds.
Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.